Show simple item record

dc.contributor.authorHowell, Anthony
dc.contributor.authorHowell, Sacha J
dc.contributor.authorEvans, D Gareth R
dc.date.accessioned2009-08-27T08:21:41Z
dc.date.available2009-08-27T08:21:41Z
dc.date.issued2003-07
dc.identifier.citationNew approaches to the endocrine prevention and treatment of breast cancer. 2003, 52 Suppl 1:S39-44 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704
dc.identifier.pmid12819938
dc.identifier.doi10.1007/s00280-003-0645-5
dc.identifier.urihttp://hdl.handle.net/10541/78794
dc.description.abstractAll major endocrine prevention approaches act via the estrogen receptor (ER). A simple hypothesis concerning ER expression and breast cancer risk is outlined. We review breast cancer prevention trials with tamoxifen, raloxifene, aromatase inhibitors, and ovarian suppression. Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshBreast Neoplasms
dc.subject.meshClinical Trials as Topic
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshRaloxifene
dc.subject.meshReceptors, Estrogen
dc.subject.meshRisk
dc.subject.meshSelective Estrogen Receptor Modulators
dc.subject.meshTamoxifen
dc.subject.meshTreatment Outcome
dc.titleNew approaches to the endocrine prevention and treatment of breast cancer.en
dc.typeArticleen
dc.contributor.departmentCRUK Department of Medical Oncology, Christie Hospital NHS Trust, University of Manchester, Wilmslow Road, M20 4BX, Manchester, UK. maria.parker@christie-tr.nwest.nhs.uken
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
html.description.abstractAll major endocrine prevention approaches act via the estrogen receptor (ER). A simple hypothesis concerning ER expression and breast cancer risk is outlined. We review breast cancer prevention trials with tamoxifen, raloxifene, aromatase inhibitors, and ovarian suppression. Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed.


This item appears in the following Collection(s)

Show simple item record